Kyverna Therapeutics, Inc. Net Change in Cash
Kyverna Therapeutics, Inc. (KYTX) reported Net Change in Cash of -$92.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-11
- Kyverna Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$91.90M.
- Kyverna Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$39.75M, a 120.96% decline year-over-year.
- Kyverna Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $189.65M, a 9137.46% increase year-over-year.
- Kyverna Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $2.05M.
- Kyverna Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $27.47M, a 55.66% decline from fiscal 2024.
- Kyverna Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $61.96M.
- Kyverna Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$3.08M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$92.29M 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | -$91.90M 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $27.47M 10-K · filed 2026-03-26 | |||
| 2025-09-30 | -$62.46M 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | -$43.18M 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | -$39.75M 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | $61.96M 10-K · filed 2026-03-26 | |||
| 2024-09-30 | $70.02M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $96.98M 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | $189.65M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$3.08M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | -$14.76M 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $15.70M 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | $2.05M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |